Page last updated: 2024-11-07

3-iodopindolol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

3-iodopindolol: RN given refers to 125I-labeled cpd(-)-isomer; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID123825
MeSH IDM0093391

Synonyms (6)

Synonym
3-iodopindolol
2-propanol, 1-((3-(iodo-125i)-1h-indol-4-yl)oxy)-3-((1-methylethyl)amino)-, (-)-
76875-01-9
1-{[3-(~125~i)iodo-1h-indol-4-yl]oxy}-3-[(propan-2-yl)amino]propan-2-ol
DTXSID60998176
(2s)-1-[(3-(125i)iodanyl-1h-indol-4-yl)oxy]-3-(propan-2-ylamino)propan-2-ol

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" Computer-assisted analysis of dose-response curves resulting from the inhibition of the binding of [125I]iodopindolol by the beta-1 and beta-2 selective compounds ICI 89,406 and ICI 118,551 revealed that approximately one-third of the beta adrenergic receptors on these cells were beta-1 receptors."( Selective regulation of beta-1 and beta-2 adrenergic receptors by atypical agonists.
Barrett, DA; Molinoff, PB; Neve, KA, 1985
)
0.27
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (94)

TimeframeStudies, This Drug (%)All Drugs %
pre-199065 (69.15)18.7374
1990's27 (28.72)18.2507
2000's2 (2.13)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other94 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]